Impact of epidermal growth factor receptor mutations on intracranial treatment response and survival after brain metastases in lung adenocarcinoma patients

Shih Hsin Hsiao, Horng Chyuan Lin, Yu Ting Chou, Sey En Lin, Chia Chun Kuo, Ming Chih Yu, Chi Li Chung

研究成果: 雜誌貢獻文章

28 引文 (Scopus)

摘要

Introduction: Brain metastases (BM) commonly occur in patients with lung adenocarcinoma and usually lead to a poor prognosis and quality of life despite of radiotherapy. Epidermal growth factor receptor ( EGFR) mutations have been widely demonstrated to be a predictive and prognostic factor for lung adenocarcinoma, however, its impact on BM from lung adenocarcinoma remains inconclusive. The present study aimed to elucidate the predictive role of EGFR mutations in BM treatment response and survival after BM in patients with lung adenocarcinoma. Material and methods: From January 2006 through February 2012, 180 of 505 lung adenocarcinoma patients developed BM during their disease course were reviewed for eligibility, and 139 patients, including 89 EGFR-mutant and 50 EGFR wild-type patients, were identified for analysis. Results: Of the patients eligible for evaluation of treatment response, up to 85% received radiotherapy and the remaining took EGFR tyrosine kinase inhibitors (TKIs) as the front modality for BM. EGFR-mutant patients, compared with EGFR wild-type patients, had significantly greater intracranial treatment response of BM (84% vs. 48%, P= 0.002), experienced higher therapeutic efficacy to radiotherapy (86% vs. 52%, P= 0.005), and had longer median survival after BM diagnosis (13.2 vs. 6.8 months, P
原文英語
頁(從 - 到)455-461
頁數7
期刊Lung Cancer
81
發行號3
DOIs
出版狀態已發佈 - 九月 2013

指紋

Epidermal Growth Factor Receptor
Neoplasm Metastasis
Mutation
Survival
Brain
Radiotherapy
Therapeutics
Adenocarcinoma of lung
Protein-Tyrosine Kinases
Quality of Life

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

引用此文

@article{0d1386d3f6e14eecb8a60f5b2f1f0ee1,
title = "Impact of epidermal growth factor receptor mutations on intracranial treatment response and survival after brain metastases in lung adenocarcinoma patients",
abstract = "Introduction: Brain metastases (BM) commonly occur in patients with lung adenocarcinoma and usually lead to a poor prognosis and quality of life despite of radiotherapy. Epidermal growth factor receptor ( EGFR) mutations have been widely demonstrated to be a predictive and prognostic factor for lung adenocarcinoma, however, its impact on BM from lung adenocarcinoma remains inconclusive. The present study aimed to elucidate the predictive role of EGFR mutations in BM treatment response and survival after BM in patients with lung adenocarcinoma. Material and methods: From January 2006 through February 2012, 180 of 505 lung adenocarcinoma patients developed BM during their disease course were reviewed for eligibility, and 139 patients, including 89 EGFR-mutant and 50 EGFR wild-type patients, were identified for analysis. Results: Of the patients eligible for evaluation of treatment response, up to 85{\%} received radiotherapy and the remaining took EGFR tyrosine kinase inhibitors (TKIs) as the front modality for BM. EGFR-mutant patients, compared with EGFR wild-type patients, had significantly greater intracranial treatment response of BM (84{\%} vs. 48{\%}, P= 0.002), experienced higher therapeutic efficacy to radiotherapy (86{\%} vs. 52{\%}, P= 0.005), and had longer median survival after BM diagnosis (13.2 vs. 6.8 months, P",
keywords = "Brain metastases, Epidermal growth factor receptor mutations, Lung adenocarcinoma, Radiotherapy, Survival after brain metastases, Treatment response",
author = "Hsiao, {Shih Hsin} and Lin, {Horng Chyuan} and Chou, {Yu Ting} and Lin, {Sey En} and Kuo, {Chia Chun} and Yu, {Ming Chih} and Chung, {Chi Li}",
year = "2013",
month = "9",
doi = "10.1016/j.lungcan.2013.06.004",
language = "English",
volume = "81",
pages = "455--461",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Impact of epidermal growth factor receptor mutations on intracranial treatment response and survival after brain metastases in lung adenocarcinoma patients

AU - Hsiao, Shih Hsin

AU - Lin, Horng Chyuan

AU - Chou, Yu Ting

AU - Lin, Sey En

AU - Kuo, Chia Chun

AU - Yu, Ming Chih

AU - Chung, Chi Li

PY - 2013/9

Y1 - 2013/9

N2 - Introduction: Brain metastases (BM) commonly occur in patients with lung adenocarcinoma and usually lead to a poor prognosis and quality of life despite of radiotherapy. Epidermal growth factor receptor ( EGFR) mutations have been widely demonstrated to be a predictive and prognostic factor for lung adenocarcinoma, however, its impact on BM from lung adenocarcinoma remains inconclusive. The present study aimed to elucidate the predictive role of EGFR mutations in BM treatment response and survival after BM in patients with lung adenocarcinoma. Material and methods: From January 2006 through February 2012, 180 of 505 lung adenocarcinoma patients developed BM during their disease course were reviewed for eligibility, and 139 patients, including 89 EGFR-mutant and 50 EGFR wild-type patients, were identified for analysis. Results: Of the patients eligible for evaluation of treatment response, up to 85% received radiotherapy and the remaining took EGFR tyrosine kinase inhibitors (TKIs) as the front modality for BM. EGFR-mutant patients, compared with EGFR wild-type patients, had significantly greater intracranial treatment response of BM (84% vs. 48%, P= 0.002), experienced higher therapeutic efficacy to radiotherapy (86% vs. 52%, P= 0.005), and had longer median survival after BM diagnosis (13.2 vs. 6.8 months, P

AB - Introduction: Brain metastases (BM) commonly occur in patients with lung adenocarcinoma and usually lead to a poor prognosis and quality of life despite of radiotherapy. Epidermal growth factor receptor ( EGFR) mutations have been widely demonstrated to be a predictive and prognostic factor for lung adenocarcinoma, however, its impact on BM from lung adenocarcinoma remains inconclusive. The present study aimed to elucidate the predictive role of EGFR mutations in BM treatment response and survival after BM in patients with lung adenocarcinoma. Material and methods: From January 2006 through February 2012, 180 of 505 lung adenocarcinoma patients developed BM during their disease course were reviewed for eligibility, and 139 patients, including 89 EGFR-mutant and 50 EGFR wild-type patients, were identified for analysis. Results: Of the patients eligible for evaluation of treatment response, up to 85% received radiotherapy and the remaining took EGFR tyrosine kinase inhibitors (TKIs) as the front modality for BM. EGFR-mutant patients, compared with EGFR wild-type patients, had significantly greater intracranial treatment response of BM (84% vs. 48%, P= 0.002), experienced higher therapeutic efficacy to radiotherapy (86% vs. 52%, P= 0.005), and had longer median survival after BM diagnosis (13.2 vs. 6.8 months, P

KW - Brain metastases

KW - Epidermal growth factor receptor mutations

KW - Lung adenocarcinoma

KW - Radiotherapy

KW - Survival after brain metastases

KW - Treatment response

UR - http://www.scopus.com/inward/record.url?scp=84881667804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881667804&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2013.06.004

DO - 10.1016/j.lungcan.2013.06.004

M3 - Article

C2 - 23871711

AN - SCOPUS:84881667804

VL - 81

SP - 455

EP - 461

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -